Ocular Therapeutix公司 OCUL 深 滬
已收盤 07-18 16:00:00 美东时间
11.33
-0.050
-0.44%
華盛通- 最 高11.57
- 今 開11.56
- 成交量 212.59万股
- 最 低 11.23
- 昨 收 11.38
- 總市值 18.01亿
- 52周最高 11.775
- 市盈率 靜 --
- 換手率 1.34%
- 52周最低 5.785
- 委 比 -63.13%
- 總股本 1.59亿
- 歷史最高 44.19
- 量 比 0.96
- 振 幅 2.99%
- 歷史最低 1.995
- 每 手 1
- 風險率 2.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Ocular Therapeutix, Inc. has unveiled its new corporate branding and website, reflecting its commitment to redefining the retina experience and addressing the challenges of retinal diseases like wet age-related macular degeneration (AMD). The rebranded logo, designed with visual accessibility and scientific innovation, symbolizes the eye and retina with vibrant colors representing human vision. The company's investigational therapy, AXPAXLI™, aim...
06-26 17:54
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 450 points on ...
06-25 00:30
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
Ocular Therapeutix, Inc. (NASDAQ: OCUL) will participate in the Clinical Trials at the Summit 2025 event in Las Vegas, NV, on June 21, 2025. The company will present updates on its investigational product candidate, AXPAXLI (OTX-TKI), including Phase 1 and 3 trial results for wet age-related macular degeneration (wet AMD) and its potential for diabetic retinopathy. Additionally, the company will discuss trial design and regulatory guidance. Ocula...
06-16 11:00
Oculis Publishes Results of 2025 Annual General Meeting
Oculis Holding AG announced the outcomes of its 2025 Annual General Meeting, where shareholders approved all agenda items, including the 2024 Annual Report, financial statements, and compensation plans. The company reported a standalone loss of CHF 5.179 million for 2024, with the accumulated loss of CHF 46.577 million carried forward. Directors and executives were discharged, and key personnel were re-elected. Shareholders approved compensation ...
06-05 08:00
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
06-02 13:32
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
Analysts' ratings for Ocular Therapeutix (NASDAQ:OCUL) over the last quarter va...
05-30 03:02
Ocular Therapeutix Announced That Enrollment In The SOL-R Registrational Trial Of Its Product Candidate Axpaxli In Wet Age-related Macular Degeneration Will Close This Week, Top-Line Readout Expected In 1Q 2026
Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjectsSOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention
05-28 19:05
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
Ocular Therapeutix announces the closure of enrollment in its SOL-R Phase 3 trial for AXPAXLI in wet AMD, having enrolled at least 555 subjects across 100 sites. SOL-R evaluates AXPAXLI dosed every 6 months vs. aflibercept every 8 weeks, with the primary endpoint assessing non-inferiority in visual acuity at Week 56. SOL-1, its complementary trial, completed randomization in December 2024 with exceptional retention, targeting a 56-week readout in...
05-28 11:00
Earnings Scheduled For May 5, 2025
Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ:RXRX) i...
05-05 16:32
